Small molecule · developed by Xenetic Biosciences
Sodium Cridanimod is an agent studied in combination with progestin therapy in endometrial cancer, in patients who have failed progestin monotherapy or who are progesterone receptor negative.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03077698 | Phase 2 | Endometrial Cancer | Terminated | XBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Endometrial Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the XBIO page.
See XBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XBIO catalysts and pipeline →